QbDVision®, an Austin, TX & Boston, MA-based product lifecycle management platform for biopharma organizations, announced that it raised a $15 million Series A to accelerate the digitization of the biomanufacturing sector.
The round was led by Northpond Ventures, a leading science- and technology-driven venture capital firm, with follow-on investment from S3 Ventures, Wanxiang Healthcare Investments, and Hudson Park Capital.
The Series A funding will accelerate the development of both our flagship product, QbDVision, and our broader mission to shape the digital future of life science manufacturing.
QbDVision is poised to accelerate the digital maturity of chemistry, manufacturing, and controls (CMC), as well as the drug development workstreams that depend on those specialized operations.
Company: CherryCircle Software, Inc.
Round: Series A
Funding Month: February 2022
Lead Investors: Northpond Ventures
Additional Investors: S3 Ventures, Wanxiang Healthcare Investments, and Hudson Park Capital
Company Website: https://www.qbdvision.com/
Software Category: Product lifecycle management platform
About the Company: QbDVision is the first modern digital CMC workspace: a cloud-based SaaS solution purpose-built for drug lifecycle management, QbDVision is designed to advance the digital maturity of the industry's chemistry, manufacturing, and controls (CMC) activities. QbDVision was purpose-built to help CMC teams make this shift – and with drug manufacturing in the pandemic’s global spotlight, the industry racing to the cloud, and a new wave of complex therapies on the horizon, demand for this software is growing rapidly. Multiple top-tier pharma and biotech organizations have already deployed QbDVision across their development cycles, giving their CMC teams a structured approach to consolidating knowledge, integrating workflows, and curating data in ways that significantly enhance operational efficiency.